Nasal Bleeding as a Potential Side Effect of Omega-3 Fatty Acids: A Case Report.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2026-04-01 DOI:10.2174/0115748863448971260303083058

Zainab Najim Abdul-Nabi

{"title":"Nasal Bleeding as a Potential Side Effect of Omega-3 Fatty Acids: A Case Report.","authors":"Zainab Najim Abdul-Nabi","doi":"10.2174/0115748863448971260303083058","DOIUrl":null,"url":null,"abstract":"Background: Omega-3 fatty acids (omega-3 FAs) have been studied for the potential treatment of Atopic Dermatitis (AD). Dietary supplementation with omega-3 FAs may help in reducing AD symptoms, including the severity of lesions, inflammation, dryness, and pruritus. Nevertheless, because of their antiplatelet action, more cautious use of these supplements has been recommended in patients who have an invasive procedure or who are receiving antiplatelet or anticoagulant therapy.Case presentation: An 18-year-old male patient with AD self-medicated with 1 gram of overthe-counter omega-3 fatty acid orally once daily for 4 weeks. Over this time, he had ten episodes of epistaxis. Baseline coagulation parameters, such as prothrombin time, activated partial thromboplastin time, and platelet count, were also normal. The patient was not on medications affecting the hemostatic process, nor were there any previous polyps or other structural nasal disorders.Conclusions: The potential of omega-3 FA supplementation to increase risk of bleeding, even at typical doses used in clinical trials, should be considered as demonstrated in this case.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":" ","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863448971260303083058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Omega-3 fatty acids (omega-3 FAs) have been studied for the potential treatment of Atopic Dermatitis (AD). Dietary supplementation with omega-3 FAs may help in reducing AD symptoms, including the severity of lesions, inflammation, dryness, and pruritus. Nevertheless, because of their antiplatelet action, more cautious use of these supplements has been recommended in patients who have an invasive procedure or who are receiving antiplatelet or anticoagulant therapy.

Case presentation: An 18-year-old male patient with AD self-medicated with 1 gram of overthe-counter omega-3 fatty acid orally once daily for 4 weeks. Over this time, he had ten episodes of epistaxis. Baseline coagulation parameters, such as prothrombin time, activated partial thromboplastin time, and platelet count, were also normal. The patient was not on medications affecting the hemostatic process, nor were there any previous polyps or other structural nasal disorders.

Conclusions: The potential of omega-3 FA supplementation to increase risk of bleeding, even at typical doses used in clinical trials, should be considered as demonstrated in this case.

查看原文本刊更多论文

鼻出血是Omega-3脂肪酸的潜在副作用：一个病例报告。

背景：Omega-3脂肪酸（Omega-3 FAs）已被研究用于治疗特应性皮炎（AD）。膳食补充omega-3脂肪酸可能有助于减轻AD症状，包括病变、炎症、干燥和瘙痒的严重程度。然而，由于其抗血小板作用，建议在有创手术或正在接受抗血小板或抗凝治疗的患者中更谨慎地使用这些补充剂。病例介绍：一名18岁男性AD患者，每日口服1克非处方omega-3脂肪酸，持续4周。在此期间，他有十次鼻出血。基线凝血参数，如凝血酶原时间，活化部分凝血活酶时间，血小板计数也正常。患者没有服用影响止血过程的药物，也没有任何息肉或其他结构性鼻部疾病。结论：即使在临床试验中使用的典型剂量下，补充omega-3脂肪酸也可能增加出血风险，应该考虑到这一点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.